Cambridge Investment Research Advisors’s Quince Therapeutics QNCX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-76	Closed	-$2K	–	4157
2026 Q1	$2K	Hold	76	–	–	﹤0.01%	3919
2025 Q4	$51K	Hold	76	–	–	﹤0.01%	3754
2025 Q3	$25K	Hold	76	–	–	﹤0.01%	3686
2025 Q2	$25K	Buy	+76	New	+$17.4K	﹤0.01%	3569

Other funds holding QNCX

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Cambridge Investment Research Advisors's QNCX Position: Q2 2026 in Review

Cambridge Investment Research Advisors sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 76 shares — an estimated $2K sold.

Cambridge Investment Research Advisors first reported a position in QNCX in Q2 2025 and held it in 4 quarters. The position peaked at $51K in Q4 2025. 1 fund tracked by Wall St. Rank holds QNCX as of Q2 2026.

Cambridge Investment Research Advisors reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
Cambridge Investment Research Advisors sold 76 Quince Therapeutics shares in Q2 2026, an estimated $2K.
Cambridge Investment Research Advisors first reported a position in Quince Therapeutics in Q2 2025 and held it in 4 quarters.
Cambridge Investment Research Advisors's Quince Therapeutics position peaked at $51K in Q4 2025.
1 fund tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.